cyproterone and Puberty--Precocious

We describe a girl, one of monozygotic (MZ) twins, with endocrine dysfunction with precocious puberty, café-au-lait nevi and polyostotic fibrous dysplasia (PFD), McCune-Albright syndrome (MAS). After treatment with cyproterone acetate for 7 years the precocious puberty and excess growth improved but the bone-age still remain advanced. The co-twin had an advanced bone-age and a small café-au-lait spot, but showed neither endocrinopathy nor fibrous dysplasia of bone. On the basis of the findings in these twins, together with those in previously reported familial cases of MAS, including two pairs of MZ twins, a 2-hit mutation hypothesis is proposed: a dominant mutation may be inherited and leads to PFD in offspring as the primary defect of MAS; the second mutation may occur in somatic cell leading to mosaicism and thus resulting in MAS. This concept explains not only sporadic cases of MAS but also reported familial cases. If we assume that the second mutation occurred in an early somatic division, it would explain the discrepancy of clinical manifestation between MZ twins.

Topics: Child, Preschool; Cyproterone; Cyproterone Acetate; Diseases in Twins; Estradiol; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Genetic Markers; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Mutation; Puberty, Precocious; Radionuclide Imaging; Twins, Monozygotic

Antiandrogens, substances that prevent androgens from expressing their activity at target cells, play an important role in the treatment of prostate cancer. The most frequently used substances have either a steroidal structure (cyproterone acetate) or a non-steroidal structure (Flutamide or Anandron). Antiandrogens have been tested both alone and in combination with treatments aimed at inhibiting testicular secretion (castration, LH-RH analogs), thereby producing complete blockade of androgen secretion and action. Patients treated by such combination protocols have often shown an improvement in the percentage of remissions and, less often, improvement in survival. Administration of antiandrogens improves the clinical symptoms of patients with benign prostatic hypertrophy, but the exact mechanism of their action requires further investigation. Cutaneous manifestations due to hyperandrogenicity (hirsutism, alopecia, acne) have also been improved by cyproterone acetate, which is often given together with estrogens (reversed sequential regime), by spironolactone or topically applied products. Finally, antiandrogens have been successfully used to treat breast cancer in men, early puberty, hypersexuality and sexual deviations.

Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Puberty, Precocious; Skin Diseases; Spironolactone

Topics: Carcinoma; Cyproterone; Female; Hirsutism; Humans; Male; Paraphilic Disorders; Prostatic Hyperplasia; Prostatic Neoplasms; Puberty, Precocious; Sex Offenses

Topics: Adolescent; Adrenal Hyperplasia, Congenital; Age Determination by Skeleton; Androgens; Child; Child Development; Child, Preschool; Chlormadinone Acetate; Choriocarcinoma; Chorionic Gonadotropin; Corpus Luteum Hormones; Cyproterone; Estradiol; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Growth Disorders; Hormones, Ectopic; Humans; Hypothyroidism; Luteinizing Hormone; Pregnancy; Pseudohypoparathyroidism; Puberty, Precocious; Sertoli Cell Tumor; Sex Factors; Testosterone

Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Bone Development; Cyproterone; Female; Growth; Hirsutism; Humans; Hypertrichosis; Libido; Male; Prostate; Prostatic Neoplasms; Puberty, Precocious; Seminal Vesicles; Sexual Dysfunction, Physiological; Skin

Topics: Androgen Antagonists; Animals; Body Height; Bone Development; Cell Differentiation; Contraceptives, Oral; Cyproterone; Epididymis; Female; Gonads; Hirsutism; Humans; Libido; Male; Pregnadienes; Pregnancy; Prostate; Prostatic Neoplasms; Puberty, Precocious; Sebaceous Glands; Seminal Vesicles; Sexual Dysfunction, Physiological; Testosterone

This study was designed to determine the benefit of therapy on final height (FHt) in girls with central precocious puberty (CPP). A total of 102 patients were evaluated--28 untreated, 26 treated with cyproterone acetate (CyA), and 48 treated with GnRH analogue (GnRHA)-and their achieved FHt was compared to the respective target height (THt). Of the untreated girls, half (14/28) had a slow course of puberty and reached THt +/- 0.5 SD (FHt 160.2 +/- 7.1, THt 159.5 +/- 6.6 cm); the other half (14/28) had an accelerated course of puberty with a FHt well below THt (FHt 150.8 +/- 4.3, THt, 159.2 +/- 5.9 cm) and in most cases (14/28) below the height-SDS of both parents. The treated girls (both regimens) reached THt above (CyA group: FHt 157.8 +/- 5.1, THt 156.8 +/- 5.1 cm; GnRHA group: 159.6 +/- 6.3, THt 157.7 +/- 5.7 cm). We conclude that without treatment the FHt of girls with CPP may be significantly compromised and that therapy is more beneficial if started before bone age exceeds 12 years. Our data also showed that for final height predictions in CPP the Bayley and Pinneau tables for average children should be used, regardless of the advanced bone age of the patients.

Topics: Administration, Oral; Adolescent; Androgen Antagonists; Body Height; Child; Child, Preschool; Cyproterone; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Injections, Subcutaneous; Luteolytic Agents; Puberty, Precocious; Treatment Outcome; Triptorelin Pamoate

Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Clinical Trials as Topic; Cyproterone; Female; Growth; Humans; Infant; Male; Puberty, Precocious

Topics: Adrenal Hyperplasia, Congenital; Buserelin; Child; Cyproterone; Cyproterone Acetate; Dexamethasone; Female; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Puberty, Precocious; Virilism

Cyproterone acetate (Androcur, Schering Co) was administered within the range of recommended doses to seven girls with central premature puberty. During the investigation period, on average within 1.8 years, in all girls regression of the premature development of sex signs and gonads occurred, as well as normalization of the vaginal cytology. The growth rate corresponded to that of girls of similar calendar age, while there was progress of bone maturation. The growth prognosis deteriorated on average by 3.7 cm per year, during the whole investigation period by as much as 5.1 cm. Cyproterone acetate did not meet the demands of adequate comprehensive treatment of children with central premature puberty.

Topics: Androgen Antagonists; Child; Cyproterone; Cyproterone Acetate; Female; Growth; Humans; Puberty, Precocious

To evaluate the effect of cyproterone acetate (CA) on the renin-angiotensin-aldosterone axis, we measured the plasma active, inactive and total renin concentrations (PARC, PIRC and PTRC) during and after CA treatment in patients with precocious puberty and genetic short stature. CA was administered at a daily dose of 150-170 mg/m2 in all subjects. PARC and PTRC were measured by immunoradiometric assays. During CA treatment, PARC, PIRC, PTRC and the PARC/PTRC ratio were significantly decreased. The plasma renin activity, measured by enzymatic assay, and the plasma aldosterone concentration were also decreased. After CA discontinuation, all of these were increased immediately along normal ranges. PARC closely correlated with plasma renin activity. These results suggest that CA produces mineralocorticoid action and suppresses the production and activation of renin.

Topics: Androgen Antagonists; Child; Cyproterone; Cyproterone Acetate; Enzyme Precursors; Female; Growth Disorders; Humans; Puberty, Precocious; Renin; Renin-Angiotensin System

Two young girls with hirsutism and premature pubarche showed nonclassical 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency. Post-ACTH increased serum delta 5-17-hydroxypregnenolone and increased ratio of delta 5-17-hydroxypregnenolone/17-hydroxyprogesterone are the most sensitive indicators of nonclassical 3 beta-HSD deficiency. Nonclassical 3 beta-HSD deficiency may not be uncommon, but most cases may have gone unrecognized. Routine assay of delta 5-17-hydroxypregnenolone should be made generally available.

Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; 3-Hydroxysteroid Dehydrogenases; Androstenedione; Child; Cyproterone; Cyproterone Acetate; Dehydroepiandrosterone; Female; Hirsutism; Humans; Hydroxyprogesterones; Paramethasone; Puberty, Precocious

Thirty-four patients (27 girls and 7 boys) with precocious puberty who had reached final height were examined in order to analyze their growth. Thirty patients were diagnosed as having idiopathic precocious puberty, while 4 patients had cerebral organic disorders. Twenty-two patients were treated with cyproterone acetate, 3 with medroxyprogesterone acetate, and 9 patients remained untreated. Growth data of these three groups showed no differences, and final height was not affected by treatment. In patients with precocious puberty, adult height was significantly more often in the lower percentiles (less than or equal to P25, corresponding to an SDS of -0.67) than expected. In both treated and untreated patients, any negative influence of the early onset of puberty on well-being in later life could not be established.

Topics: Adaptation, Psychological; Adolescent; Adult; Body Height; Cyproterone; Cyproterone Acetate; Female; Humans; Interview, Psychological; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Models, Biological; Puberty, Precocious; Statistics as Topic

The data are provided on the continuous use of Androcur in the treatment of genuine precocious puberty in children. The drug produced a beneficial effect in 100% of cases in respect to suppression of the secondary sexual characters, menstrual function in girls, and behavior normalization in boys. During treatment, the improvement of the growth prognosis was negligible. Stabilization of the processes of osseous maturation requires administration of the maximal drug doses, which may suppress glucocorticoid function of the adrenals. This fact should be taken into account during treatment, particularly on its discontinuation. The treatment should be discontinued according to the schedule similar to that applied in glucocorticoid discontinuation.

Topics: Androgen Antagonists; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Drug Evaluation; Female; Humans; Male; Prognosis; Puberty, Precocious; Time Factors

Topics: Androgen Antagonists; Brain; Brain Neoplasms; Child, Preschool; Cyproterone; Cyproterone Acetate; Humans; Male; Pineal Gland; Puberty, Precocious; Tomography, X-Ray Computed

A reversed-phase high-performance liquid chromatographic method for the simultaneous determination of cyproterone acetate (CPA), 15 beta-hydroxycyproterone acetate (15 beta-OH-CPA) and cyproterone (CP) was reported. This method was specific, sensitive, precise, easy and rapid for determination of the serum concentrations of these steroids in patients receiving CPA. Although no peak corresponding to CP was observed for serum, peaks corresponding to CPA and 15 beta-OH-CPA were detected and well separated in all subjects undergoing long-term CPA therapy. In these patients, there seemed to be a dose-dependent relationship between the amount of CPA administered and the serum concentrations of these steroids, and the serum concentrations of CPA were either similar or low compared with those of 15 beta-OH-CPA. In conclusion, this simplified method is thought to be very valuable for studies on the pharmacokinetics of CPA and 15 beta-OH-CPA, and on the relationship between the CPA dosage and the therapeutic or side effects on adrenal and gonadal steroid production.

Topics: Administration, Oral; Chromatography, High Pressure Liquid; Cyproterone; Cyproterone Acetate; Humans; Puberty, Precocious

Topics: Androgens; Child; Cyproterone; Cyproterone Acetate; Growth; Humans; Male; Puberty, Precocious

We have studied the endocrinological pattern in a girl with McCune-Albright syndrome. The young patient showed: normal prepubertal serum levels of gonadotropins, fluctuating estrogen concentrations, which sometimes were similar to the levels in adult women of fertile age, hyperprolactinemia with galactorrhea, ovarian cysts. The effects of treatment with antiandrogen drug, cyproterone acetate, and of a LHRH agonist, buserelin (less than D-Ser[TBU(8)6-des-gly NH2.10 greater than LHRH ethylamide), were studied. Cyproterone acetate with or without buserelin did not fully suppress estradiol concentrations. On the other hand, surgical resection of these cysts resulted in both clinical and endocrinological remission. It is likely that in this case of McCune-Albright syndrome precocious puberty was a result of ovarian estrogen secretion, while pubertal activation of the hypothalamus-pituitary axis was absent. Hyperprolactinemia, which appeared after the beginning of the combined therapy with buserelin and cyproterone acetate, was probably due to the elevated estrogen levels.

Topics: Buserelin; Child, Preschool; Cyproterone; Cyproterone Acetate; Estradiol; Estrogens; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Galactorrhea; Gonadotropin-Releasing Hormone; Humans; Lactation Disorders; Luteinizing Hormone; Ovary; Prolactin; Puberty, Precocious

Treatment of precocious puberty of central origin is aimed at controlling the development of sexual characteristics and improving final height. Increased growth rate is one of the major clinical symptoms, accompanied by an even more marked advance in bone age. Medroxyprogesterone acetate and cyproterone acetate have provided almost satisfactory control of pubertal characteristics, but with accompanying adrenal insufficiency. The data with regard to growth and bone maturation are contradictory. LHRH analogues have recently become available, and provide good control of gonadotrophin secretion. In a series of 21 cases (13 girls, 8 boys), a significant decrease in growth rate was achieved in both sexes with an LHRH analogue, with a significant increase in the height age/bone age ratio; control of gonadal secretions was also obtained. These results are only preliminary, but provide hope that the final height of these children will be improved.

Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Gonadotropin-Releasing Hormone; Humans; Infant; Male; Medroxyprogesterone; Puberty, Precocious; Triptorelin Pamoate

Forty-four patients (42 f, 2 m) with precocious puberty (31 idiopathic, 1 familial, 7 cerebral, 5 McCune-Albright) were treated with cyproterone acetate for periods of 1-8.75 years in different (P less than 0.05) daily dosages of 117 +/- 6.1 mg/m2 per day (mean +/- SEM, group A, N = 20) and 60.8 +/- 2.42 mg/m2 per day (group B, N = 24). Thirty-three girls had experienced menarche before therapy at a mean age of 4.89 +/- 0.42 years. Treatment was started at a chronologic age of 5.45 +/- 0.33 years in the girls and 5.74 +/- 1.34 years in the boys. At the time of evaluation, 31 of our patients had reached final height. With respect to the effects of treatment on statural growth, the Standard Deviation Scores were retrospectively determined for height, weight, and growth velocity. The initial Bayley-Pinneau height predictions were compared with final height and target height, and the skeletal maturation was studied. There were no significant differences between those parameters in the patients of group A and B or between treated and untreated subjects as far as final height and target height were concerned. It is concluded that cyproterone acetate administered orally at daily doses from 50-150 mg/m2 does not improve statural growth of patients with precocious puberty.

Topics: Body Height; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Dose-Response Relationship, Drug; Female; Follicle Stimulating Hormone; Growth; Humans; Luteinizing Hormone; Male; Puberty, Precocious

We have examined the growth and skeletal maturation of 19 children (6 male, 13 female) with central precocious puberty. The aetiology in nine patients (5 male, 4 female) was secondary to a hypothalamic hamartoma. Six children (2 male, 4 female) received no treatment whereas 13 children (4 male, 9 female) were treated with cyproterone acetate in a mean dose of 68 mg/m2 per day (range, 34-260) for a mean duration of 4.5 years (range, 0.8-7.9). There was no significant difference between height SDS for bone age at the beginning and end of observation in either treated or untreated groups. No significant relationship between the mean dose of cyproterone acetate used and change in height SDS for bone age could be determined. We conclude that cyproterone acetate has no beneficial effect on the growth prognosis of children with central precocious puberty.

Topics: Body Height; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Dose-Response Relationship, Drug; Female; Hamartoma; Humans; Hypothalamic Neoplasms; Male; Prognosis; Puberty, Precocious

We describe three patients in whom at the age of 4-7 yrs the diagnosis adrenogenital syndrome (21-hydroxylase deficiency) was made. There was no salt-loss. Two boys presented with precocious pubic hair development and increased growth velocity and bone maturation. The third patient was a severely virilized girl raised as a boy until she was 4 yrs old. Following an extensive psychiatric evaluation, it was decided to raise her as a girl and feminoplasty was performed. Clinical and biochemical evidence of central precocious puberty was present in one boy at the time of diagnosis at age 7 and developed under hydrocortisone substitution therapy in the two other patients. The precocious puberty was treated in two patients with the anti-androgen cyproterone acetate. In one boy suppression of pituitary gonadotropin secretion was obtained by LH-RH analogue (Buserelin) treatment.

Topics: Adrenal Hyperplasia, Congenital; Buserelin; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Disorders of Sex Development; Female; Genitalia; Humans; Hydrocortisone; Male; Puberty, Precocious

A "transient" precocious puberty with ovarian follicular cysts was observed in four girls. Each girl presented with several successive and transient episodes of development of secondary sex characters: breast development, areolar pigmentation, brown abdominal median line were the clinical signs of oestrogen secretion. At the time of referral, plasma and urinary gonadotropins levels were low in the prepubertal range while plasma oestradiol concentrations were elevated, in the pubertal range. At this time, as well as during each episode of "pubertal" development, the gonadotropins response to GnRH stimulation was blunted. In contrast, a prepubertal or pubertal response was observed when the clinical symptoms of estrogenization had resumed. Ultrasonography showed one or several ovarian follicular cysts. In two cases, the treatment with the GnRH agonist, D-TRP 6 GnRH [Decapeptyl (R)], was successful, suggesting a central dysfunction

Topics: Child; Child, Preschool; Cyproterone; Estradiol; Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Ovarian Cysts; Ovarian Follicle; Pituitary Hormone-Releasing Hormones; Puberty, Precocious; Remission, Spontaneous; Triptorelin Pamoate

We have studied four girls with central precocious puberty treated with cyproterone acetate for a mean of 3.6 years (range 1.5-6.3 years). Pelvic ultrasound assessment demonstrated suppression of the ovarian morphology of central precocious puberty despite the presence of spontaneous pulsatile gonadotrophin secretion at night. We suggest that the previously reported effects on gonadotrophin secretion induced by cyproterone acetate therapy, administered in recommended doses, are minor and that the predominant effect of cyproterone acetate in the treatment of girls with central precocious puberty is direct inhibition of ovarian steroidogenesis.

Topics: Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Follicle Stimulating Hormone; Humans; Infant; Luteinizing Hormone; Ovary; Puberty, Precocious; Secretory Rate; Ultrasonography

This paper reviews the clinical findings, pituitary gonadotrophin reserve and plasma oestradiol, neurological findings and pelvic ultrasound appearance in 47 girls with precocious puberty starting before the age of 7 years. Of the 39 girls who had air encephalograms or cranial CT scans, 19 showed intracranial abnormalities (hamartomas 11; hydrocephalus 5; optic glioma 2; arachnoid cyst 1). There was no significant difference in the peak serum luteinizing hormone and follicle-stimulating hormone responses to intravenous gonadotrophin stimulating hormone in girls with and without intracranial lesions. Pelvic ultrasound examination showed development of the ovaries, uterus, and vagina similar to that seen in normal puberty. Treatment with cyproterone acetate (50-100 mg/day) in 26 girls resulted in arrest of breast development and suppression of menstruation, but a definite effect on growth was not documented.

Topics: Brain Diseases; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Echoencephalography; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Medroxyprogesterone; Puberty, Precocious; Tomography, X-Ray Computed

Topics: Cyproterone; Cyproterone Acetate; Follow-Up Studies; Hamartoma; Humans; Hypothalamic Neoplasms; Infant; Male; Puberty, Precocious; Time Factors; Tuber Cinereum

Topics: Antibodies; Cyproterone; Female; Gonadotropin-Releasing Hormone; Humans; Male; Medroxyprogesterone; Puberty, Precocious

Of a group of 79 patients (45 males, 34 females) with myelomeningocele (MMC), 52 had associated hydrocephalus. Three of the hydrocephalic patients (two arrested and one shunted) were found to have precocious sexual development. Endocrine investigations confirmed true isosexual precocity. Hydrocephalus is known to be associated with precocious puberty, but the occurrence of sexual precocity in patients with hydrocephalus in conjunction with MMC has not been described to date. As the clinical diagnosis of hydrocephalus in a young child is often unreliable, routine computerized tomographic scans of all MMC patients is advised, and even patients with arrested hydrocephalus should be followed carefully for signs of precocious puberty. In addition, a high incidence (15%) of cryptorchidism was found in the group of MMC patients reviewed.

Topics: Child; Child, Preschool; Contraceptive Agents, Male; Cryptorchidism; Cyproterone; Cyproterone Acetate; Female; Humans; Hydrocephalus; Intracranial Pressure; Male; Meningomyelocele; Puberty, Precocious

Six girls and one boy with precocious puberty were treated with a superactive LHRH analogue (D-TRP6-LHRH) for periods ranging from 1 year to 2 years and 3 months. In the first phase of the treatment it was administered in combination with cyproterone acetate (CyA) to counteract an early stimulatory effect until inhibition of gonadotrophin secretion was achieved. The gonadotrophin-dependent signs i.e. gonadarche, showed sustained arrest and even regression. Gonadal sex steroids decreased but the adrenal androgens were unaffected. In four patients who showed progression of the angrogen-dependent signs (adrenarche), despite suppression of gonadotrophins, increasing the dosage of the LHRH analogue was ineffective and combined therapy with CyA was reinstituted in three of them because of accelerated growth and bone maturation. It is concluded that at present the treatment of choice for precocious puberty is the daily administration of a superactive LHRH analogue such as D-TRP6-LHRH, together with CyA in the initial stage, and at a later state if adrenarche progresses too rapidly.

Topics: Androgens; Bone Development; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Estradiol; Female; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Hormones; Humans; Male; Puberty, Precocious; Testosterone; Triptorelin Pamoate

Plasma prolactin (PRL) response to synthetic thyrotropin-releasing hormone (TRH) was studied in six patients with pubertal gynecomastia, five patients with premature thelarche and nine female patients with idiopathic precocious puberty. The basal concentration of plasma PRL was higher (p less than 0.01) in pubertal gynecomastia as compared to control, while baseline plasma PRL levels in premature thelarche and idiopathic precocious puberty were similar to those in controls. Plasma PRL level after TRH in patients with pubertal gynecomastia was higher (p less than 0.01) than that in control, while plasma PRL responses to TRH in idiopathic precocious puberty and premature thelarche were comparable to those controls. The TRH-induced PRL release was more enhanced during treatment with cyproterone acetate (CA) than before CA therapy in four of five patients with idiopathic precocious puberty. These data suggest that the enhanced release of PRL may, at least in part, contribute to breast enlargement in pubertal gynecomastia and that seen in idiopathic precocious puberty and premature thelarche may not depend on the PRL secretion. The prolonged administration of CA enhances the PRL responsiveness to TRH.

Topics: Adolescent; Breast; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Gynecomastia; Humans; Infant; Male; Prolactin; Puberty, Precocious; Radioimmunoassay; Thyrotropin-Releasing Hormone

Sitting height (SH) and sub-ischial leg length (SLL) were measured in 10 boys and 16 girls with precocious puberty; the patients were aged from 1.5 to 13.4 years at the time. Standard deviation scores (SDS) calculated for chronological age and bone age showed higher scores for SH than for SLL in all but two patients, both girls: the differences between the SDS for SH and SLL were more marked in the boys. The findings indicate that growth of the trunk is usually greater than growth of the legs in precocious puberty, particularly in boys.

Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Humans; Leg; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Posture; Puberty, Precocious

Topics: Age Determination by Skeleton; Androgen Antagonists; Child; Cyproterone; Cyproterone Acetate; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Puberty, Precocious; Retrospective Studies

Topics: Adolescent; Androgen Antagonists; Brain Neoplasms; Child, Preschool; Cyproterone; Cyproterone Acetate; Diagnosis, Differential; Female; Hamartoma; Humans; Puberty, Precocious

Authors describe a case of a boy aged 8-10/12 years with precocious puberty associated with Von Recklinghausen's disease. He was treated with cyproterone acetate (100 mg/m2/24 h oral doses) and controlled for a period of two years. He shows very few effects of puberal physical signs and improvement of his sexual behavioral area. They have evaluated growth evolution by different parameters and couldn't appreciate any improvement because of the advanced bone age (13-6/12 years) when treatment was started.

Topics: Adult; Age Determination by Skeleton; Body Height; Child; Child Behavior Disorders; Cyproterone; Cyproterone Acetate; Female; Humans; Hypothalamic Neoplasms; Male; Neurofibromatosis 1; Puberty, Precocious; Skin Neoplasms

Topics: Arachnoid; Child, Preschool; Cyproterone; Cyproterone Acetate; Cysts; Humans; Male; Metrizamide; Puberty, Precocious; Sella Turcica; Tomography, X-Ray Computed

Topics: Adolescent; Child; Cyproterone; Female; Humans; Male; Medroxyprogesterone; Pituitary Hormone-Releasing Hormones; Puberty, Precocious

Thirty-four boys with true precocious puberty were observed: In 28, precocious puberty was related to intracranial causes (17 tumors, 11 other lesions), in 3, it was due to extrapituitary gonadotropin-secreting tumors and in 3 it appeared idiopathic. The clinical development of sex characteristics was slower than the advance of bone age and the increase in hormone levels (plasma testosterone and pituitary gonadotropin reserve as measured by the LH-RH test). Cyproterone treatment seemed more effective than medroxyprogesterone, with respect to both sexual development and evolution of the bone age/height age ratio or the predictable adult height.

Topics: Body Height; Child; Child, Preschool; Cyproterone; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Infant; Luteinizing Hormone; Male; Medroxyprogesterone; Puberty, Precocious; Testosterone

Topics: Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Follicle Stimulating Hormone; Hamartoma; Humans; Hypothalamic Neoplasms; Infant; Luteinizing Hormone; Male; Puberty, Precocious; Tuber Cinereum

Topics: Blood Glucose; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Growth Hormone; Humans; Insulin; Puberty, Precocious; Time Factors

Topics: Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Puberty, Precocious

In order to evaluate the secretory patterns of luteinizing and follicle-stimulating hormones in various forms of abnormal sexual development, plasma levels of these hormones were measured every 20-30 minutes during sleep in 9 patients with true precocious puberty and 2 patients with primary hypogonadism. Seven patients with idiopathic precocious puberty and 2 patients with organic CNS lesion-related precocious puberty exhibited fluctuating plasma concentrations of these hormones that resembled findings in normal pubertal subjects who had significantly increased concentrations of plasma luteinizing hormone during sleep. Two patients with primary hypogonadism also showed episodic fluctuation of both hormones and augmented luteinizing hormone concentrations during sleep. These results suggest that the pubertal sleep-related gonadotropin secretion is dependent on the sleep-entrained CNS mechanism, and that the central nervous system plays an important role in sexual maturation.

Topics: Adolescent; Central Nervous System; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; Luteinizing Hormone; Puberty; Puberty, Precocious; Sleep

Adrenal function was studied in thirty-two children with precocious sexual development who were being treated with cyproterone acetate (CPA) at doses ranging from 68 to 175 mg. m2. day for periods lasting from 2 to 79 months. In eighteen children the adrenocortical function evaluation was made before and during CPA treatment. In these eighteen patients, the mean basal plasma cortisol level during the morning hours was 11.2 +/- 4.6 micrograms/dl (m +/- SD) before treatment and fell significantly to 7.2 +/- 4.1 micrograms/dl (P less than 0.02) during therapy. In fifteen patients tested during insulin hypoglycaemia the cortisol peak fell from 21.6 +/- 5.5 micrograms/dl before treatment to 16.7 +/- 6.8 micrograms/dl (P less than 0.05) during CPA therapy. There was a significant inverse correlation between this peak and the dose of CPA but no correlation was found between the cortisol response and duration of treatment. In eight of twenty patients tested, urinary free cortisol levels were undetectable during treatment. No change in basal plasma ACTH levels were demonstrated using standard radioimmunoassay techniques. In the patient receiving the highest dose of CPA and showing complete suppression of the adrenal axis, prolonged stimulation with ACTH-Depot demonstrated a responsive adrenal gland. Addition of a replacement dose of cortisol to the CPA treatment led to the rapid development of the typical signs of Cushing's syndrome. It was concluded that despite the evidence of adrenal suppression by CPA, cortisol supplementation is not necessary and may not even be contraindicated.

Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Child; Cyproterone; Cyproterone Acetate; Female; Humans; Hydrocortisone; Male; Puberty, Precocious

A 6-year-old girl with central (true) precocious puberty was successfully treated with a combination of the luteinising hormone releasing hormone analogue (D-Trp6)-LH-RH and cyproterone acetate. This treatment led to an almost complete arrest of gonadotrophin and oestrogen secretion, induced regression of pubertal signs, and markedly slowed bone maturation. It is suggested that the paradoxical refractoriness of the gonadotrophic and gonadal cells induced by long-term treatment with LH-RH agonists can be exploited in the treatment of precocious puberty.

Topics: Bone Development; Child; Cyproterone; Cyproterone Acetate; Depression, Chemical; Drug Therapy, Combination; Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Puberty, Precocious; Triptorelin Pamoate

Seven children with precocious puberty were treated with cyproterone acetate and their adrenal function studied. In each child the drug caused significant adrenal hypofunction which was secondary to adrenocorticotrophic hormone suppression. None of these children had clinical evidence of adrenal hypofunction and it is assumed that the drug has glucocorticoid-like properties. Children receiving cyproterone acetate should carry information to warn doctors of this effect since they may require steroid cover during illness.

Topics: Adrenal Cortex; Adrenal Insufficiency; Adrenocorticotropic Hormone; Child; Child, Preschool; Cyproterone; Female; Growth Hormone; Humans; Hydrocortisone; Male; Puberty, Precocious

Topics: Adolescent; Adrenal Hyperplasia, Congenital; Body Height; Child; Child, Preschool; Cyproterone; Cyproterone Acetate; Female; Humans; Infant; Japan; Male; Puberty, Precocious; Sexual Maturation; Surveys and Questionnaires

Topics: Age Factors; Child; Child, Preschool; Cyproterone; Danazol; Female; Gonadotropin-Releasing Hormone; Growth; Humans; Medroxyprogesterone; Pregnadienes; Puberty, Precocious

Topics: Acne Vulgaris; Adolescent; Adrenal Cortex Function Tests; Adrenal Hyperplasia, Congenital; Child; Cyproterone; Cyproterone Acetate; Dose-Response Relationship, Drug; Female; Hirsutism; Humans; Male; Paraphilic Disorders; Puberty, Precocious

Twenty-four girls with sexual precocity who had been treated with cyproterone acetate were followed for periods from 1 to 8 1/2 years after the discontinuation of therapy. It was found that their further pubertal development and the resumption or appearance of menstruation followed a natural course within the wide limits of physiological variability. It is concluded that puberty resumes its natural course following cessation of treatment with cyproterone acetate, and it is assumed that the reproductive ability of these patients will not be affected.

Topics: Adolescent; Child; Cyproterone; Cyproterone Acetate; Female; Follow-Up Studies; Humans; Menarche; Puberty; Puberty, Precocious

Topics: Age Factors; Cyproterone; Cyproterone Acetate; Female; Fibrous Dysplasia, Polyostotic; Humans; Infant; Puberty, Precocious; Time Factors

Topics: Age Determination by Skeleton; Bone and Bones; Breast; Child; Child, Preschool; Cyproterone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Prolactin; Puberty, Precocious

Topics: Child; Child, Preschool; Cyproterone; Follicle Stimulating Hormone; Humans; Infant; Luteinizing Hormone; Male; Medroxyprogesterone; Puberty, Precocious; Sex Hormone-Binding Globulin; Testosterone

A mongol child suffereing from hypothyroidism who presented with precocious puberty is described. A presumptive diagnosis of idiopathic precocious puberty was first made and she was treated initially with medroxyprogesterone acetate, and later, with cyproterone acetate. The diagnosis of primary hypothyroidism was made late because of misleading results of protein bound iodine estimations. Subsequently, thyroid medication resulted in a prompt return to the normal range of the previously elevated levels of plasma gonadotrophins, thyroid stimulating hormone and plasma and urinary oestrogens, but the serum prolactin remained elevated for several months after therapy was begun.

Topics: Child; Cyproterone; Down Syndrome; Female; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Humans; Hypothyroidism; Luteinizing Hormone; Medroxyprogesterone; Puberty, Precocious; Serum Globulins; Thyroid Function Tests; Thyrotropin-Releasing Hormone; Thyroxine

16 girls with precocious puberty have been studied. Following low dosage cyproterone acetate (CA) therapy (mean daily dosage 65 mg/m2BSA) a beneficial effect on growth and skeletal maturation was observed. During high dosage therapy (150 mg/m2 per day) endocrinological studies were performed in 10 of these patients. There was no significant difference in HGH levels (insulin- and arginine-test), T3 and TSH values (TRH-test) between patients and controls, T4 concentration was significantly increased. Basal prolactin levels and prolactin response to TRH was definitely elevated. Oral glucose load and arginine infusion resulted in a significantly enhanced insulin release. There was a significant reduction in basal LH levels and an increase in FSH response to LH-RH. Basal and diurnal plasma cortisol values were markedly reduced and the cortisol release due to corticotrophin injection, lysinevasopressin (LVP) injection and insulin-hypoglycemia as well. A definite increase in basal ACTH levels was observed, during LVP- and insulin-hypoglycemia test ACTH concentrations were within or significantly above normal range. In our patients a primary adrenocortical insufficiency due to CA treatment was evident.

Topics: Arginine; Body Height; Cyproterone; Glucose; Growth; Humans; Hydrocortisone; Insulin; Lypressin; Male; Pituitary Hormones, Anterior; Puberty, Precocious; Thyrotropin-Releasing Hormone; Thyroxine

The most important therapeutic problems of female puberty and adolescence are discussed, including high stature, amenorrhoea, oligomenorrhea, pubertas tarda, anovulation, anorexia, anisomastia, hypermastia. Indications for treatment are given and the possibilities for a prophylactic medicine in this age group are stressed.

Topics: Acne Vulgaris; Adolescent; Amenorrhea; Anorexia Nervosa; Breast Diseases; Child; Cyproterone; Drug Combinations; Endocrine System Diseases; Estradiol Congeners; Ethinyl Estradiol; Female; Growth Disorders; Hirsutism; Humans; Menstruation Disturbances; Obesity; Oligomenorrhea; Progesterone Congeners; Puberty, Precocious

Topics: Child; Cyproterone; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Hypothalamo-Hypophyseal System; Ovary; Pituitary Hormones, Anterior; Puberty, Precocious

Topics: Child; Cyproterone; Female; Humans; Psychosexual Development; Puberty, Precocious

8 children with precocious puberty were treated with cyproterone acetate (CPA). During treatment there were no definite clinical signs of depressed adrenocortical function. The plasma cortisol concentrations were grossly depressed and the diurnal cortisol rhythm was abolished. Two months after discontinuation of CPA treatment the adrenocortical function had greatly improved. The lysin-vasopressin stimulation test revealed in one child a normal, in another child an exaggerated ACTH response during CPA therapy. Fasting plasma ACTH concentrations were elevated compared with normal controls, but they were very low compared with patients with Addison's disease. The results suggest that CPA has a twofold effect leading to adrenocortical insufficiency: i.e., inhibition of cortisol secretion by the adrenals themselves and inhibition of ACTH secretion at the hypothalamopitiuitary level.

Topics: Adolescent; Adrenal Cortex; Adrenocorticotropic Hormone; Child; Child, Preschool; Circadian Rhythm; Cyproterone; Fasting; Female; Humans; Hydrocortisone; Infant; Male; Puberty, Precocious

Topics: Adrenocorticotropic Hormone; Age Determination by Skeleton; Body Height; Child; Cyproterone; Female; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Male; Puberty, Precocious

Topics: Age Factors; Body Height; Child; Child, Preschool; Cyproterone; Female; Humans; Puberty, Precocious

Topics: Cerebral Ventricle Neoplasms; Child, Preschool; Cyproterone; Diagnosis, Differential; Electroencephalography; Epilepsy; Female; Hamartoma; Heart Defects, Congenital; Humans; Hypothalamo-Hypophyseal System; Hypothalamus; Laughter; Puberty, Precocious; Seizures

Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Child; Chlormadinone Acetate; Cyproterone; Dermatitis, Seborrheic; Female; Fertility; Hirsutism; Humans; Menstruation; Puberty, Precocious; Skin Diseases

Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Adrenal Glands; Adult; Child; Child, Preschool; Cyproterone; Depression, Chemical; Female; Humans; Hydrocortisone; Infant; Male; Puberty, Precocious

It is reported on the possibilities of the application of anti-androgenics, especially of cyproterone acetate. The indication extends to hirsutism, sexual deviations, growth disturbances in pubertas praecox as well as diseases of the prostate. Particularly strong standard are to be applied in the treatment of fertile women, as there exists the danger of an intrauterine feminisation of male foetuses, when a pregnancy was not absolutely excluded. Side-effects and results of animal experiments are mentioned. The therapeutic mechanism of the anti-androgenics can be explained with the help of a concurrency mechanism at the androgen receptor or acceptor.

Topics: Acne Vulgaris; Animals; Cricetinae; Cyproterone; Female; Gynecomastia; Hirsutism; Humans; Libido; Male; Menstruation Disturbances; Paraphilic Disorders; Pregnancy; Prostatic Hyperplasia; Puberty, Precocious; Rats

9 children with precocious puberty were treated over a period of 6 months to 6 3/12 years with Cyproteron acetate or an Ethisterone derivate. LH-RH tests with radioimmunological estimations of LH and FSH were performed before therapy was begun, during and after completion of treatment. In children with untreated precocious puberty the mean basal LH levels were the same as in normal prepubertal children but the increase and the peak values after i.v. LH-RH were found to be considerably greater than in normals. In the treated patients this stimulatable LH release was suppressed; after completion of therapy it was again elevated. The basal FSH levels in untreated children were elevated; however the increase and the peak values were comparable to the collective norm. Results were not altered considerably by therapy, however these parameters were given elevated after completion of therapy. Despite the marked suppression of stimulatable LH by therapy acceleration of bone age is practically not affected. After completion of therapy this drug-induced suppression of gonadotropines is promptly reversible.

Topics: Age Determination by Skeleton; Child; Child, Preschool; Cyproterone; Ethisterone; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Puberty, Precocious; Radioimmunoassay; Time Factors

A synthetic steroid compound derived from testosteron (isoxazol-ethisterone), Danazol, with gonadotropin-depressing activity, was used in the treatment of 4 cases of idiopathis sexual precocity (age 2 1/2 to 4 years) and in 10 cases of severe pubertal gynaecomastia. In sexual precocity the suppression of menstruation as well as of breast-enlargement was good, while the suppression of acceleration of longitudinal growth and bone maturation was inferior compared with cyproteron-acetate. In most boys with gynaecomastia a marked regression of breast enlargement occurred within a few weeks or months. With the dosage used (200-300 mg/day in the sexual precocity patients, 300-400 mg in the gynaecomastia patients) the changes in plasma hormone levels (LH, FSH, progesterone, estradiol, testosterone) were within a non significant range. Depression of testosterone seemed to be a rather regular finding. No untoward side-effects of the medication were noticed in the 14 patients studied. In summary, Danazol did not show any advantages compared with the compounds used in the treatment of isosexual precocity sofar. In contrast, the drug proved to have useful effects in pubertal gynecomastia, a condition which in severe degrees certainly deserves medical treatment.

Topics: Adolescent; Adult; Age Determination by Skeleton; Child; Child, Preschool; Cyproterone; Danazol; Drug Evaluation; Female; Gynecomastia; Humans; Male; Pregnadienes; Puberty, Precocious; Time Factors

Ten girls with precocious puberty ranging in age from 7 to 10 7/12 years who were treated with oral cyproterone acetate on a long term basis, were subjected to LH-RH tests, prior to and 3 to 16 months after the institution of therapy. Cyproterone acetate was given in doses from 60 to 153 mg/m2, which proved to be clinically effective, as evidenced by the slowing down of sexual maturation. The basal levels of LH were found to be unaffected by therapy and corresponded to the pubertal stages of the individual girls. The peak increment of LH after LH-RH stimulation was markedly suppressed by the therapy. FSH secretion and its responsiveness to LH-RH was not affected by cyprotereone acetate. The basal levels of FSH were higher during therapy than before, but the peak FSH increment remained the same. An escape phenomenon in the LH peak response was evident in 2 patients upon retesting after prolonged therapy. It is possible that the antigonadotrophic action of cyproterone acetate is due to its progestational nature.. 10 girls with precocious puberty ranging in age from 7 to 10 7/12 years who were treated with oral cyproterone acetate on a long-term basis, were subjected to LH-RH tests, prior to an 3-16 months after the institution of therapy. Cyproterone acetate was given in doses from 60 to 153 mg/sq m, which proved to be clinically effective, as evidenced by the slowing down of sexual maturation. The basal levels of LH were found to be unaffected by therapy and corresponded to the pubertal stages of the individual girls. The peak increment of LH after LH-RH stimulation was markedly suppressed by the therapy. Follicle stimulating hormone (FSH) secretion and its responsiveness to LH-RH was unaffected by cyproterone acetate. The basal levels of FSH were higher during therapy than before, but the peak FSH increment remained the same. An escape phenonmenon in the LH peak response was evident in 2 patients upon retesting after prolonged therapy. It is possible that the antigonadotrophic action of cyproterone acetate is due to its progestational nature.

Topics: Child; Cyproterone; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Puberty, Precocious

Topics: Child, Preschool; Cyproterone; Diencephalon; Female; Humans; Infant; Pituitary Gland; Puberty, Precocious

Pasma prolactin response to the acute injection of sulpiride (1.5 mg/k BW im) was measured at 0800-0900h in 4 girls with idiopathic precocious puberty before and after 6 to 11 months of continuous therapy with 50 mg daily of cyproterone acetate (CA) orally administered. Two additional girls were examined after 26 and 28 months of therapy, respectively. Mean baseline prolactin concentrations were significantly higher in untreated girls with precocious puberty as compared to that of normal controls of the same chronological age and of a comparable degree of sexual maturation (14.5 +/- 1.9 SE vs. 7.4 +/- 1.8 SE ng/ml and vs. 9.5 +/- 1.8 ng/ml, respectively; P less than .02). Treatment with CA caused a significant further increase of plasma prolactin concentration (P less than .02 as compared to pre-treatment values); no correlation was observed between prolactin concentration and duration of treatment. No significant change in the integrated areas of prlactin response to sulpiride occurred after prolonged CA therapy. The results suggest that in idiopathic precocious puberty the action of CA upon the hypothalamic-hypophyseal complex is not solely antigonadotropic and that prolactin secretion is enhanced in patients given this drug.

Topics: Child; Child, Preschool; Cyproterone; Female; Humans; Kinetics; Prolactin; Puberty, Precocious; Sulpiride

Topics: Adrenal Insufficiency; Child; Child, Preschool; Cyproterone; Female; Humans; Puberty, Precocious

Topics: Child; Child, Preschool; Cyproterone; Estrogens; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Ovary; Pituitary Gland, Anterior; Puberty, Precocious; Testosterone

Topics: Adult; Child; Cyproterone; Drug Evaluation; Female; Humans; Libido; Male; Paraphilic Disorders; Prostatic Neoplasms; Puberty, Precocious; Virilism

Topics: Adrenocorticotropic Hormone; Adult; Child; Cyproterone; Female; Humans; Hydrocortisone; Male; Puberty, Precocious; Sexual Dysfunction, Physiological

50 mg daily of cyproterone acetate (CA) were orally administered for 8 to 35 months to 7 girls with idiopathic precocious puberty. Plasma levels of FSH and LH, cortisol, testosterone, estradiol, and progesterone were measured in 6 patients before treatment. Compared with control subjects of the same chronological age, significantly higher values were found for gonadotropins, testosterone, and estradiol. After treatment, no significant variation was observed in FSH and LH levels; testosterone was reduced in the majority of the cases without significant decline in mean values; estradiol fell significantly and returned in the prepubertal range. The plasma gonadotropin pattern following exogenously administered luteinizing hormone-releasing hormone (LRH, 100 mug iv) was characterized before treatment by an exaggerated LH response both in terms of maximum level (32.02 +/- 4.35 SE mIU/ml; prepubertal controls: 16.20 +/- 1.45 SE mIU/ml) and maximum increment above baseline values (25.36 +/- 2.84 SE mIU/ml; prepubertal controls: 13.78 +/- 1.71 mIU/ml); plasma FSH response was similar to prepubertal subjects. Treatment with CA caused a significant reduction of mean LH response (P less than .025 in comparison with pre-treatment values for maximum level and maximum increment), whereas effect on FSH response was minimal. In all patients examined, a gonadotropin release from the pituitary after the injection of synthetic LRH was evident also after several months of therapy.

Topics: Child; Child, Preschool; Cyproterone; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Ovary; Pituitary Gland; Progesterone; Puberty, Precocious; Testosterone

Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs of sexual maturation, but the oral form proved to be superior. Only the younger patients with a bone age under 11 years showed a beneficial effect upon linear growth and bone maturation. No side effects were noted, but additional advantageous effects upon behaviour and sociability were. It is concluded that at present cyproterone acetate by mouth is the drug of choice in the treatment of precocious puberty. The treatment should be initiated as early as possible to attain maximum benefit.

Topics: Administration, Oral; Adolescent; Behavior; Body Weight; Bone Development; Child; Child, Preschool; Cyproterone; Female; Growth; Humans; Injections, Intramuscular; Male; Puberty, Precocious; Skinfold Thickness

Topics: Androgen Antagonists; Animals; Cyproterone; Female; Humans; Infertility, Female; Libido; Male; Prostatic Hyperplasia; Puberty, Precocious; Rats; Spermatogenesis

Fourteen girls and one boy with isosexual precocious puberty were submitted to LHRH stimulation tests, during and without therapy with cyproterone acetate. In addition, fourteen girls with isosexual precocious puberty not receiving any therapy were tested and served as controls. It was found that cyproterone acetate induces suppression of the responsiveness of the pituitary gland to secrete LH on LHRH stimulation. Daily oral therapy was found to be more effective than the regimen of intramuscular depot injections. These findings demonstrate that cyproterone acetate has an antigonadotrophic effect.

Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cyproterone; Female; Gonadotropin-Releasing Hormone; Humans; Injections, Intramuscular; Luteinizing Hormone; Male; Pituitary Gland; Puberty, Precocious; Radioimmunoassay

The effects of cyproterone acetate (CA), daily oral administration of 100 mg/m2, on the levels of urinary androgen excretion and velocity of skeletal maturation were studied in 8 girl patients with precocious puberty. Under therapy, testosterone excretion fell within a short time, and velocity of skeletal maturation normalized when the treatment was prolonged. Other beneficial effects such as stoppage of vaginal bleeding and no further growth of breast size and public hair, were also observed. Of 3 subjects, who were given CA for a period of 2--3 yrs, 2 showed further increments in testosterone excretion levels.

Topics: Androgens; Bone Development; Child; Child, Preschool; Cyproterone; Female; Humans; Puberty, Precocious

Topics: Androsterone; Body Height; Body Weight; Bone Development; Child; Child, Preschool; Cyproterone; Dehydroepiandrosterone; Etiocholanolone; Female; Humans; Male; Prognosis; Puberty, Precocious; Testosterone; Time Factors

Topics: Age Determination by Skeleton; Androgen Antagonists; Body Height; Bone Development; Child; Child, Preschool; Cyproterone; Growth Disorders; Growth Hormone; Hamartoma; Humans; Hypopituitarism; Male; Pregnadienes; Prognosis; Puberty, Precocious; Skull Neoplasms

Topics: 17-Ketosteroids; Age Determination by Skeleton; Androgen Antagonists; Body Height; Bone Development; Child; Child, Preschool; Cyproterone; Estrogens; Female; Gonadotropins; Growth Disorders; Humans; Male; Pregnadienes; Prognosis; Puberty, Precocious

Topics: 17-Ketosteroids; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Body Height; Child; Child, Preschool; Cyproterone; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Growth Hormone; Humans; Luteinizing Hormone; Pregnadienes; Puberty, Precocious; Testosterone

Topics: Age Factors; Child; Child, Preschool; Cyproterone; Female; Humans; Luteinizing Hormone; Male; Puberty, Precocious; Radioimmunoassay

Topics: Adolescent; Adult; Cyproterone; Female; Humans; Male; Puberty, Precocious; Sex Offenses; Sexual Dysfunction, Physiological

Topics: Acetates; Brain Diseases; Brain Neoplasms; Child; Child, Preschool; Chlormadinone Acetate; Cyproterone; Female; Hamartoma; Humans; Hypothalamus; Male; Medroxyprogesterone; Progestins; Puberty, Precocious